Manila Times Business
BioVersys announces first patient first visit in Phase 2b RIV-CARE trial of BV100
Ad hoc announcement pursuant to Art. 53 LRBV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and bloodstream infections (BSI) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). RIV-CARE (NCT07431307), an open label Phase 2b clinical trial, aims to compare BV100 plus low-dose polymyxin B plus ceftazidime/avibactam, or plus cefiderocol to best-available
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Global Times: Long March spirit sails on in China’s modern navy, spurs innovation and self-reliance
4h ago
Keeping Classics Alive and Evolving: 2026 iCAUR International User Summit Concludes with New Advances in Future Classic Design and Customization Ecosystem
4h ago
South Carolina police close investigation into Hayden Panettiere's death
4h ago
Debate on California’s Prop 40 Wealth Tax Backfiring is Topic of Latest Family Enterprise USA ‘Family Business Briefs’ Podcast
4h ago